Gyre Therapeutics, Inc. financial data

Symbol
GYRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
12770 High Bluff Drive, Suite 150, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
CATALYST BIOSCIENCES, INC. (to 10/27/2023), TARGACEPT INC (to 8/19/2015)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 327 % +1.23%
Quick Ratio 30.4 %
Debt-to-equity 76.5 %
Return On Equity -114 % -615%
Return On Assets -69 % -75.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 93.5M shares +146%
Common Stock, Shares, Outstanding 85.8M shares +126%
Entity Public Float 11.1M USD -80.1%
Common Stock, Value, Issued 85K USD +130%
Weighted Average Number of Shares Outstanding, Basic 85.6M shares +34.7%
Weighted Average Number of Shares Outstanding, Diluted 103M shares +30.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 105M USD -20.5%
Research and Development Expense 2.78M USD -7.78%
Selling and Marketing Expense 57.1M USD -1.64%
General and Administrative Expense 20.7M USD +136%
Costs and Expenses 181M USD +10.3%
Operating Income (Loss) -76.1M USD -4017%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -77.8M USD -15272%
Income Tax Expense (Benefit) 5.82M USD -55%
Net Income (Loss) Attributable to Parent -83.6M USD -575%
Earnings Per Share, Basic -1.4 USD/shares -64.7%
Earnings Per Share, Diluted -1.46 USD/shares -64%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.9M USD +612%
Cash, Cash Equivalents, and Short-term Investments 33.5M USD +54.4%
Accounts Receivable, after Allowance for Credit Loss, Current 564K USD -43.9%
Inventory, Net 6.38M USD
Other Assets, Current 1.51M USD
Assets, Current 54.8M USD +968%
Deferred Income Tax Assets, Net 5.16M USD
Property, Plant and Equipment, Net 24.4M USD
Operating Lease, Right-of-Use Asset 1.98M USD
Other Assets, Noncurrent 2.77M USD +1546%
Assets 125M USD +1157%
Accounts Payable, Current 303K USD +91.8%
Liabilities, Current 14.7M USD +725%
Operating Lease, Liability, Noncurrent 1.1M USD
Other Liabilities, Noncurrent 2K USD
Liabilities 26.8M USD +315%
Accumulated Other Comprehensive Income (Loss), Net of Tax -946K USD
Retained Earnings (Accumulated Deficit) -73.4M USD +82.3%
Stockholders' Equity Attributable to Parent 63.2M USD +1696%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 98.5M USD +15.4%
Liabilities and Equity 125M USD +1157%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 2.88M USD -72.3%
Net Cash Provided by (Used in) Financing Activities 658K USD
Net Cash Provided by (Used in) Investing Activities -7.22M USD +5.6%
Common Stock, Shares Authorized 400M shares +300%
Common Stock, Shares, Issued 85.8M shares +126%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.72M USD -225%
Deferred Tax Assets, Valuation Allowance 63.8M USD +13.8%
Deferred Tax Assets, Gross 68.7M USD +1545%
Operating Lease, Liability 1.8M USD
Payments to Acquire Property, Plant, and Equipment 231K USD -86.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -87.6M USD -47.4%
Lessee, Operating Lease, Liability, to be Paid 1.91M USD
Property, Plant and Equipment, Gross 29.8M USD
Operating Lease, Liability, Current 694K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 617K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 766K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 114K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 286K USD
Deferred Tax Assets, Operating Loss Carryforwards 40.7M USD -0.25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.83M USD
Operating Lease, Payments 139K USD +9.45%
Additional Paid in Capital 134M USD -65.1%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 112K USD -28.6%
Depreciation, Depletion and Amortization 415K USD +50.4%
Deferred Tax Assets, Net of Valuation Allowance 4.7M USD +15%
Share-based Payment Arrangement, Expense 7.15M USD -43.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%